Complete financial analysis of CalciMedica, Inc. (CALC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CalciMedica, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- METISA Metalúrgica Timboense S.A. (MTSA4.SA) Income Statement Analysis – Financial Results
- Bank First Corporation (BFC) Income Statement Analysis – Financial Results
- Kiwi Property Group Limited (KPG.NZ) Income Statement Analysis – Financial Results
- AcBel Polytech Inc. (6282.TW) Income Statement Analysis – Financial Results
- Business Online Public Company Limited (BOL.BK) Income Statement Analysis – Financial Results
CalciMedica, Inc. (CALC)
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| Gross Profit | -58.00K | -52.00K | -519.00K | -395.00K | -303.00K | -175.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.36M | 14.11M | 18.90M | 20.96M | 30.58M | 22.97M |
| General & Administrative | 0.00 | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.46M | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Other Expenses | 0.00 | 2.96M | 0.00 | 2.16M | 72.00K | 0.00 |
| Operating Expenses | 21.82M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Cost & Expenses | 21.88M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Interest Income | 0.00 | 575.00K | 126.00K | 143.00K | 393.00K | 192.00K |
| Interest Expense | 0.00 | 0.00 | 126.00K | 143.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| EBITDA | -34.19M | -7.64M | -35.30M | -27.14M | -36.73M | -28.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.88M | -36.18M | -35.95M | -29.83M | -37.50M | -28.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.48M | 28.36M | 126.00K | 2.30M | 465.00K | 192.00K |
| Income Before Tax | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -109.90K | 2.39M | -2.00M | -538.00K | -393.00K | 13.86K |
| Net Income | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| EPS Diluted | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| Weighted Avg Shares Out | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
| Weighted Avg Shares Out (Dil) | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses,...
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA...
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE...
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today...
CalciMedica Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses,...
CalciMedica Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses,...
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically...
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m.
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the...
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that...
Source: https://incomestatements.info
Category: Stock Reports